Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Avalo Therapeutics (AVTX) has 3 years of Finished Goods data on file, last reported at $46705.0 in Q4 2019.

• Quarterly Finished Goods fell 90.62% year-over-year to $46705.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $46705.0 (down 90.62% YoY) and the FY2019 annual result came in at $46705.0, down 90.62% from the prior year.
• Finished Goods retreated to $46705.0 in Q4 2019, from $497949.0 in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $560499.0 in Q4 2017 to a low of $46705.0 in Q4 2019.
• A 3-year average of $368384.3 and a median of $497949.0 in 2018 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2018 — Finished Goods slipped 11.16% — and 2019, when it tumbled 90.62%.
• Tracing AVTX's Finished Goods over 3 years: stood at $560499.0 in 2017, then decreased by 11.16% to $497949.0 in 2018, then plunged by 90.62% to $46705.0 in 2019.
• The last three Finished Goods figures came in at $46705.0 (Q4 2019), $497949.0 (Q4 2018), and $560499.0 (Q4 2017), per Business Quant data.